AstraZeneca (AZN) CFO Dr. Aradhana Sarin joins Nicole Petallides to give an overview of the company and discuss its most recent earnings. AZN’s 3Q adjusted EPS came in at $0.86 versus an estimated $0.80 and revenue came in at $11.49B versus an estimated $11.44B. Sarin discusses AZN’s recent pipeline momentum. AMZN’s FY23 guidance sees core EPS increasing by low double-digit to low-teens percentage. Tune in to find out more about the stock market today.